Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab more value in squamous cell carcinomas or adenocarcinomas at ASCO GI 2016
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab more value in squamous cell carcinomas or adenocarcinomas at ASCO GI 2016